- Policy
- Saxenda's misuse and abuse are discussed
- by Lee, Tak-Sun Mar 26, 2020 06:12am
- The Ministry of Food and Drug Safety plans to release and disclose self-injection system safety management measures such as 'Saxenda', which has recently increased in sales volume as a weight management supplement. However, in the course of the discussion, there was still a large difference in opinion between doctors and pharmacists. Pati
- Policy
- Domestic drugs, access to the Chilean procurement market
- by Lee, Tak-Sun Mar 26, 2020 06:11am
- The KHIDI (Director Deok-cheol Kwon) announced that it has signed a Memorandum of Understanding (MOU) with Chile's Health Procurement Service (CENABAST, Valentin Diaz Gracia, Chief Executive Officer) and Korean companies to advance into public procurement of pharmaceuticals in Chile. The Chilean Health Procurement Authority (CENABAST) mana
- Policy
- Sanofi’s new laxative line-up DulcoSoft approved in Korea
- by Lee, Tak-Sun Mar 26, 2020 06:11am
- The world’s leading constipation relief Dulcolax maker Sanofi is expanding the brand line-up. The global company means to consolidate the leadership in the competitive Korean laxative market with new oral solution. On Mar. 23, Sanofi-Aventis Korea has received Ministry of Food and Drug Safety’s (MFDS) approval on DulcoSoft powder
- Company
- FDA approves Phase III Actemra COVID-19 trial
- by An, Kyung-Jin Mar 26, 2020 06:11am
- A late-phase clinical trial in patients with severe case of the 2019 novel coronavirus (COVID-19) would be conducted with Actemra, solely distributed by JW Pharmaceutical in Korea. Roche Group’s Genentech has announced on Mar. 23 the U.S. Food and Drug Administration (FDA) has approved Actemra’s (tocilizumab) Phase III clinical trial
- Company
- Celltrion, clinical trial in COVID-19 in July
- by Lee, Seok-Jun Mar 26, 2020 06:10am
- Chairman Jeong-jin Seo of Celltrion said on the 23rd, "This July, human clinical trials will be started for the development of COVID-19 treatments". He added, "It is possible to develop a therapeutic antibody for 1 million people per month after human administration". Chairman Seo shared this business plan through an online press conferenc
- Policy
- Researchers from Korea start verifying COVID-19 treatments
- by Lee, Tak-Sun Mar 25, 2020 09:57am
- Treatments such as Hydroxychloroquine, used in COVID-19 infected patients, have entered clinical trials in earnest. Large hospitals, such as the AMC, have tried to verify safety and effectiveness through sponsor-investigator trials. Other hospitals besides the AMC have also been reported to apply for a clinical trial for Hydroxychloroquin
- Company
- General hospitals codes in new antiosteoporosis Evenity
- by Eo, Yun-Ho Mar 25, 2020 06:03am
- Korean general hospitals are adding osteoporosis treatment Evenity in the prescription code. The pharmaceutical industry sources report Amgen’s Evenity (romosozumab) has been passed by drug committees at the Big Five general hospitals like Samsung Medical Center, Seoul Asan Medical Center and Severance Hospital, as well as Gangnam Sever
- Company
- Balloon effect from impurity measures?
- by Chon, Seung-Hyun Mar 25, 2020 06:03am
- Recently, the number of new anti-ulcer drugs that enter the market is rapidly increasing. As the alternative drug market expanded after the Ranitidine’s withdrawal due to excessive detection of impurities in September last year, pharmaceuticals are also actively targeting the generic market. In addition to H2 receptor antagonists such as Fa
- Policy
- Advanced payment for COVID-19, expanded
- by Lee, Hye-Kyung Mar 25, 2020 06:02am
- care benefits, which were currently applied only to medical institutions in Daegu and Gyeongbuk. However, the support organizations are dedicated to the prevention of COVID-19 spread and treatment of patients and are limited to medical institutions, excluding pharmacies, The NHIS is expanding the nation's special cases of advance payment for
- Policy
- Eligibility standards on RSA change for better accessibility
- by Kim, Jung-Ju Mar 25, 2020 06:02am
- The risk sharing agreement (RSA) system implemented to enhance reimbursement access on an expensive drug would be amended and applied on follow-on drugs as well. To this date, multinational pharmaceutical companies and related industry have been strongly demanding for the change. They are now anticipating the change to resolve issues in
